Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lucie M. Heinzerling
Observed names:
Heinzerling, Lucie M.,
L Heinzerling,
L. Heinzerling,
Lucie Heinzerling,
Lucie M Heinzerling
Institutions:
Friedrich-Alexander-Universität Erlangen-Nürnberg,
LMU Klinikum,
Universitätsklinikum Erlangen,
Ludwig-Maximilians-Universität München
Observed institutions:
Friedrich-Alexander-Universität Erlangen-Nürnberg,
LMU Klinikum,
Massachusetts General Hospital,
Universitätsklinikum Erlangen,
Comprehensive Cancer Center Erlangen,
Ludwig-Maximilians-Universität München
show all 6
ORCID:
0000-0001-5718-3643
Observed ORCID:
0000-0001-5718-3643
OpenAlex ID:
A5102961913
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
2021
·
Paaladinesh Thavendiranathan
, Lili Zhang
, et al.
·
Journal of the American College of Cardiology
·
223
PDF
Immune checkpoint inhibitor-associated myocarditis: a novel risk score
2025
·
John R Power
, Charles Dolladille
, et al.
·
European Heart Journal
·
123
PDF
Dedifferentiated and Undifferentiated Melanomas: Report of 35 New Cases With Literature Review and Proposal of Diagnostic Criteria
2020
·
Abbas Agaimy
, Robert Stoehr
, et al.
·
The American Journal of Surgical Pathology
·
105
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
2024
·
Theresa Ruf
, Rafaela Kramer
, et al.
·
European Journal of Cancer
·
64
PDF
Current Melanoma Treatments: Where Do We Stand?
2021
·
Alvaro Moreira
, Lucie Heinzerling
, et al.
·
Cancers
·
60
PDF
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
2022
·
Leonie Müller-Jensen
, Sarah Zierold
, et al.
·
European Journal of Cancer
·
48
PDF
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
2023
·
Dirk Tomsitz
, Theresa Ruf
, et al.
·
Cancers
·
41
PDF
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction
2025
·
Yen-Chou Chen
, Charles Dolladille
, et al.
·
JACC CardioOncology
·
34
Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity
2023
·
Leonie Müller-Jensen
, Axel R Schulz
, et al.
·
Neuro-Oncology
·
27
Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level
2024
·
Barbara Meier-Schiesser
, Christine Zecha
, et al.
·
JAAD International
·
23
PDF
Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study
2024
·
Theresa Ruf
, Farnaz Rahimi
, et al.
·
Journal of Immunotherapy
·
19
Checkpoint inhibitor‐induced bullous pemphigoid differs from spontaneous bullous pemphigoid
2024
·
N. Kramer
, G. Müller
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
19
PDF
BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
2021
·
Stefanie Hoyer
, Valentina Eberlein
, et al.
·
International Journal of Molecular Sciences
·
17
PDF
Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients
2022
·
Tina Jost
, Barbara Schuster
, et al.
·
Strahlentherapie und Onkologie
·
16
PDF
Checkpoint-inhibitor induced Polyserositis with Edema
2022
·
Sarah Zierold
, Larissa Semra Akcetin
, et al.
·
Cancer Immunology Immunotherapy
·
15
PDF
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
2023
·
Anastasia Tsakmaklis
, Fedja Farowski
, et al.
·
BMC Cancer
·
14
PDF
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
2023
·
L. Weiss
, K. Heinrich
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
14
PDF
Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients
2024
·
Dirk Tomsitz
, Katrin Kerl
, et al.
·
Journal of the American Academy of Dermatology
·
12
Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation
2022
·
Julian Schlüter
, Sarah Cunningham
, et al.
·
Immunobiology
·
11
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling
2026
·
Déborah Suissa
, Marine Fidelle
, et al.
·
Nature Medicine
·
9
PDF
Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
2024
·
Malte Beckmann
, Julian Schlüter
, et al.
·
Cancer Immunology Immunotherapy
·
9
Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma
2025
·
Amélie Ciernik
, Laure Ciernik
, et al.
·
The Oncologist
·
8
PDF
MAPK blockade, toxicities, pathogenesis and management
2020
·
Alvaro Moreira
, Céleste Lebbé
, et al.
·
Current Opinion in Oncology
·
8
Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis
2025
·
Giulia Pesch
, Ignazio Piseddu
, et al.
·
Cancer Immunology Research
·
7
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG
2025
·
Sören Reinhard
, Jochen Sven Utikal
, et al.
·
European Journal of Cancer
·
7
PDF
Show more works
View as search
Works count:
73
Citation count:
987
H-index:
15
I10-index:
19
Year
Topic
Type